Marci K. Sontag, PhD1,2; Careema Yusuf, MPH3; Scott D. Grosse, PhD4; Sari Edelman, MPH3; Joshua I. Miller, MPH1,2; Sarah McKasson, MPH1,2; Yvonne Kellar-Guenther, PhD1,5; Marcus Gaffney4; Cynthia F. Hinton, PhD6; Carla Cuthbert, PhD6; Sikha Singh, MHS3; Jelili Ojodu, MPH3; Stuart K. Shapira, MD, PhD4 (View author affiliations)
What is already known about this topic?
Previous modeled estimates of the number of infants identified by newborn screening (NBS), in conjunction with CDC’s Hearing Screening and Follow-up Survey data, predicted approximately 10,500 cases of NBS disorders in the United States in 2006 (25.5 per 10,000 births).
What is added by this report?
This first national report based on reported cases from all 50 states estimates that approximately 12,900 births might be identified each year with an NBS disorder included in the study (34.0 per 10,000 births).
What are the implications for public health practice?
NBS continues to be one of the most successful public health interventions, offering early detection and intervention to all infants, regardless of geographic, ethnic, or socioeconomic differences.
Newborn screening (NBS) identifies infants at risk for congenital disorders for which early intervention has been shown to improve outcomes (1). State public health programs are encouraged to screen for disorders on the national Recommended Uniform Screening Panel (RUSP), which increased from 29 disorders in 2005 to 35 in 2018.* The RUSP includes hearing loss (HL) and critical congenital heart defects, which can be detected through point-of-care screening, and 33 disorders detected through laboratory screening of dried blood spot (DBS) specimens. Numbers of cases for 33 disorders on the RUSP (32 DBS disorders and HL) reported by 50 U.S. state programs were tabulated. The three subtypes of sickle cell disease (SCD) listed as separate disorders on the RUSP (S,S disease; S,beta-thalassemia; and S,C disease) were combined for the current analysis, and the frequencies of the resulting disorders were calculated relative to annual births. During 2015–2017, the overall prevalence was 34.0 per 10,000 live births. Applying that frequency to 3,791,712 live births in 2018,† approximately 12,900 infants are expected to be identified each year with one of the disorders included in the study. The most prevalent disorder is HL (16.5 per 10,000), and the most prevalent DBS disorders are primary congenital hypothyroidism (CH) (6.0 per 10,000), SCD (4.9 per 10,000), and cystic fibrosis (CF) (1.8 per 10,000). Notable changes in prevalence for each of these disorders have occurred since the previous estimates based on 2006 births (2). The number of infants identified at a national level highlights the effect that NBS programs are having on infant health through early detection, intervention, and potential improved health, regardless of geographic, racial/ethnic, or socioeconomic differences.
A 2008 report estimated that in 2006, 6,439 U.S. infants were identified with any of 27 DBS disorders included on the RUSP (2). Because complete data were available from only four states, that estimate was derived from nonlinear modeling techniques applied to 2001–2006 NBS data reported by those states, extrapolated to 2006 U.S. births adjusted for the race/ethnicity distributions (2). The objectives of the current study were to update national estimates of infants with NBS disorders included on the RUSP and to compare these updated prevalence estimates with those previously reported.
The current study is based on data reported for 33 of the 35 disorders included on the RUSP among infants born during 2015–2017, the most recent years of available national data. States reported aggregate numbers of confirmed cases of 32 RUSP DBS disorders to the Association of Public Health Laboratories’ Newborn Screening Technical assistance and Evaluation Program (NewSTEPs) (3), a Health Resources and Services Administration-funded data repository. States were requested to apply uniform case definitions established by clinical and public health experts and adopted by NewSTEPs (4). All 50 state programs reported data to NewSTEPs; however, several states were unable to report data for some of the DBS disorders included in this study. In addition, four disorders (severe combined immunodeficiency, glycogen storage disease type II [Pompe disease], mucopolysaccharidosis type 1, and X-linked adrenoleukodystrophy) were added to the RUSP since 2006, for which screening was implemented in some states during the 3-year data collection time frame. Aggregate numbers of confirmed cases of HL among 2015–2017 births were reported from 48 states to CDC’s Early Hearing Detection and Intervention (EHDI) Hearing Screening and Follow-up Survey (HSFS) (5).§ Colorado did not report HL data for the 2015–2017 period, and Minnesota reported data for 2017 only. The District of Columbia did not report data for any of the DBS NBS disorders, so it was excluded from the analysis.
Because SCD is generally considered a condition comprising multiple subtypes,¶ the three SCD subtypes on the RUSP were combined into a single disorder for the current assessment. Two RUSP disorders were not included in this assessment: critical congenital heart defects, because few states require reports (6), and spinal muscular atrophy, because it was not added to the RUSP until after the 2015–2017 period covered in this study.**
Annual births for each state during 2015–2017 and nationally in 2018 (the most recent year with data) were ascertained from CDC WONDER.†† For each of the disorders, prevalence estimates for 2015–2017 were calculated. For each disorder, denominator data included only births during months for which universal screening was available in the state and the state reported data for the disorder to NewSTEPs or HSFS. To estimate annual case counts, the 2015–2017 prevalence rates calculated empirically in this assessment were applied to the total U.S. birth cohort for 2018. Prevalence estimates for NBS disorders among infants born during 2015–2017 were compared with estimates among infants born in 2006. For 27 DBS disorders on the RUSP, 2006 estimates were ascertained from the NBS modeling study report (2). These data were supplemented with HL data reported to HSFS for 2006.
Prevalence estimates for each of the disorders and all disorders combined are presented for all 50 states (Table), and the prevalence of each disorder is presented by state in a heat map (Supplementary Table, https://stacks.cdc.gov/view/cdc/93107). During 2015–2017, the birth prevalences for any of the disorders, any of the DBS disorders, and HL were estimated at 34.0, 17.5, and 16.5 per 10,000, respectively. Prevalences of individual DBS disorders varied from 0.01 to 6.0 per 10,000. The most prevalent DBS disorders were CH (6.0 per 10,000), SCD (4.9 per 10,000), and CF (1.8 per 10,000); together, these accounted for 73% of all cases of DBS disorders.
The estimated 2006 prevalence of any DBS disorder on the RUSP, other than type 1 tyrosinemia, was 15.6 per 10,000 (6,439 per 4,138,349) births (2). The estimated number of HL cases in 2006 based on HSFS data was 4,097 (9.9 per 10,000) (Table). Thus, the total 2006 prevalence estimate for any of the assessed disorders on the RUSP was 25.5 per 10,000 infants. The RUSP disorders prevalence estimate of 34.0 per 10,000 reported here for infants born during 2015–2017 is a 33% increase since 2006, with more than three-quarters (78%) of that increase driven by HL.
Notable changes in prevalence between 2006 and 2015–2017 occurred for several disorders. Among the more prevalent DBS disorders, the observed rate during 2015–2017 was lower than the modeled rate in 2006 for CF (−1.19 per 10,000) and higher for SCD (0.65 per 10,000) and CH (0.79 per 10,000). The observed rate for HL during 2015–2017 was substantially higher (16.5 per 10,000) than the rate based on 2006 HSFS data (9.9 per 10,000). Variable prevalences by state were observed, with HL, CH, and SCD being the most prevalent in most states (Supplementary Table, https://stacks.cdc.gov/view/cdc/93107).
Applying the 2015–2017 prevalence estimate of 34.0 per 10,000 live births to the number of U.S. live births in 2018 (3,791,712), approximately 12,900 infants (6,646 with DBS disorders and 6,259 with HL) are expected to be identified annually with one of the included NBS disorders.
This is the first published report of the prevalence of NBS disorders in the United States using cases reported by all 50 states. Based on 2018 live births, approximately 12,900 U.S. infants are predicted to be identified each year through NBS with one of the included RUSP disorders (DBS and HL). This total reflects only a modest increase of 3.2% in the number of infants identified with a DBS disorder between 2006 (6,439 infants) and the expected number in 2018 (6,646 infants), even though four new disorders with an estimated 459 infants identified in 2018 (7.1% increase) were added to the RUSP since 2006. This small increase in the number of reported cases is less than one half of the expected increase from the new disorders if the number of births had remained the same. It is the net result of an increase in the prevalence of identified infants with DBS disorders since 2006 for both existing and new RUSP disorders and a marked reduction in the number of births in the United States after 2006. In contrast, the number of infants identified with HL increased substantially from an estimated 4,097 in 2006 to an expected 6,259 in 2018; this large increase likely reflects improvements in follow-up documentation by EHDI programs (5).
Although the overall prevalence of DBS disorders increased from 2006 (15.6 per 10,000) to 2015–2017 (17.5 per 10,000), changes in individual disorder prevalence estimates varied. Random variation and small numbers might have affected the estimates for each period. Notable changes in prevalence for each of the three most prevalent DBS disorders were observed. First, the lower prevalence of CF during 2015–2017 compared with 2006 might reflect a reduction in live births with CF under the influence of widespread neonatal and prenatal screening and reproductive counseling (7). Second, the increase in CH prevalence might be a continuation of long-term trends related to a higher proportion of U.S. births to Hispanic parents, among other factors (8). Finally, the higher prevalence of SCD might reflect more births to parents originating from countries where SCD is relatively common§§ (9). Variations in prevalence of individual disorders across states might reflect differences in the geographic distribution of disease-causing genetic variants and differences in screening methods, case definitions, follow-up, and reporting practices.
The findings in this report are subject to at least four limitations. First, the prevalence rates calculated for the newest disorders that have been added to the RUSP are based on data from only a few states across a short period, making these rates less robust than the rates for the other disorders. However, changes in estimated prevalences for these rare disorders are not likely to have a large impact on the overall rate of infants identified with an NBS disorder. Second, the study did not include two disorders on the RUSP (spinal muscular atrophy and critical congenital heart defects) because of lack of data; future studies could incorporate these disorders once reliable national data are available. Third, differences among the reporting practices of both NBS and EHDI programs potentially limit the interpretation of these data. Although NewSTEPs recommends uniform case definitions (5), not all NBS programs applied these definitions to the cases submitted. Finally, state prevalence estimates for individual disorders might be affected by 1) newborns born in one state and screened in another or 2) newborns from surrounding states born and screened in a state other than their resident state; however, national-level estimates would not be affected. A strength of the study is that the prior prevalence estimates of NBS disorders are modeled estimates based on four states, whereas the current study relies on reported numbers of disorders from 50 states.
The number of infants identified by NBS at a national level highlights the scope of the effect that NBS programs are having as they identify infants at risk for significant morbidity and mortality and refer them for recommended intervention. NBS continues to be a major public health achievement, offering population-based early detection, intervention, and potential improved outcomes to all infants, regardless of geographic, racial/ethnic, or socioeconomic differences (10).
Newborn screening programs in the following jurisdictions: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
1Center for Public Health Innovation, CI International, Littleton, Colorado; 2Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado; 3Association of Public Health Laboratories, Silver Spring, Maryland; 4National Center on Birth Defects and Developmental Disabilities, CDC; 5Department of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado; 6Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, CDC.
- CDC. CDC Grand Rounds: newborn screening and improved outcomes. MMWR Morb Mortal Wkly Rep 2012;61:390–3. PubMedexternal icon
- CDC. Impact of expanded newborn screening—United States, 2006. MMWR Morb Mortal Wkly Rep 2008;57:1012–5. PubMedexternal icon
- Ojodu J, Singh S, Kellar-Guenther Y, et al. NewSTEPs: the establishment of a national newborn screening technical assistance resource center. Int J Neonatal Screen 2018;4:1. CrossRefexternal icon
- Sontag MK, Sarkar D, Comeau AM, et al. Case definitions for conditions identified by newborn screening public health surveillance. Int J Neonatal Screen 2018;4:16. CrossRefexternal icon PubMedexternal icon
- Subbiah K, Mason CA, Gaffney M, Grosse SD. Progress in documented early identification and intervention for deaf and hard of hearing infants: CDC’s Hearing Screening and Follow-up Survey, United States, 2006–2016. J Early Hear Detect Interv 2018;3:1–7. PubMedexternal icon
- Glidewell J, Grosse SD, Riehle-Colarusso T, et al. Actions in support of newborn screening for critical congenital heart disease—United States, 2011–2018. MMWR Morb Mortal Wkly Rep 2019;68:107–11. CrossRefexternal icon PubMedexternal icon
- Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM. Association between carrier screening and incidence of cystic fibrosis. JAMA 2009;302:2573–9. CrossRefexternal icon PubMedexternal icon
- Shapira SK, Lloyd-Puryear MA, Boyle C. Future research directions to identify causes of the increasing incidence rate of congenital hypothyroidism in the United States. Pediatrics 2010;125(Suppl 2):S64–8. CrossRefexternal icon PubMedexternal icon
- Wang Y, Kennedy J, Caggana M, et al. Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. Genet Med 2013;15:222–8. CrossRefexternal icon PubMedexternal icon
- Brosco JP, Grosse SD, Ross LF. Universal state newborn screening programs can reduce health disparities. JAMA Pediatr 2015;169:7–8. CrossRefexternal icon PubMedexternal icon
|Disorder||No. of cases reported 2015–2017†||No. of births§||Rate (cases per 10,000 births)||2006 modeled rate*||Rate difference||Expected no. of cases per year¶|
|Amino acid disorders|
|Classical phenylketonuria and hyperphenylalaninemia||691||11,750,876||0.59||0.52||0.07||223|
|Maple syrup urine disease||64||11,750,876||0.05||0.06||−0.01||21|
|Citrullinemia, type I||75||11,750,876||0.06||0.06||0.01||24|
|Tyrosinemia, type I||22||11,750,876||0.02||NR*||—*||7|
|Organic acid disorders|
|Glutaric acidemia, type I||104||11,750,876||0.09||0.09||−0.00||34|
|3-Methylcrotonyl-CoA carboxylase deficiency||293||11,750,876||0.25||0.24||0.01||95|
|Methylmalonic acidemia (methylmalonyl-CoA mutase)||22||11,750,876||0.02||0.12||−0.10||7|
|Methylmalonic acidemia (cobalamin disorders)||43||11,750,876||0.04||0.03||0.01||14|
|Holocarboxylase synthase deficiency||6||11,750,876||0.01||0.01||−0.00||2|
|Fatty acid oxidation disorders|
|Medium-chain acyl-CoA dehydrogenase deficiency||689||11,750,876||0.59||0.58||0.01||222|
|Very long-chain acyl-CoA dehydrogenase deficiency||206||11,750,876||0.18||0.17||0.01||66|
|Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency||26||11,750,876||0.02||0.03||−0.01||8|
|Trifunctional protein deficiency||6||11,750,876||0.01||0.00||0.00||2|
|Carnitine uptake defect/carnitine transport defect||138||11,750,876||0.12||0.21||−0.09||45|
|SCD (includes S,S disease, S,beta-thalassemia, and S,C disease)||5,808||11,750,876||4.94||4.29||0.65||1,874|
|Primary congenital hypothyroidism||6,629||11,049,582||6.00||5.21||0.79||2,275|
|Congenital adrenal hyperplasia||819||11,750,876||0.70||0.49||0.21||264|
|Lysosomal storage disorders|
|Glycogen storage disease, type II (Pompe)||62||1,828,917||0.34||—**||—**||129|
|Mucopolysaccharidosis, type 1||11||965,027||0.11||—**||—**||43|
|Other DBS screening disorders|
|Severe combined immunodeficiencies||220||9,763,119||0.23||—**||—**||85|
|Point-of-care screening disorders††|
|Infants expected to be detected with an NBS disorder||12,905|
|Prevalence per 10,000 births||34.0|
|Infants expected to be detected via DBS screening||6,646|
|Prevalence per 10,000 births, DBS only||17.5|
Suggested citation for this article: Sontag MK, Yusuf C, Grosse SD, et al. Infants with Congenital Disorders Identified Through Newborn Screening — United States, 2015–2017. MMWR Morb Mortal Wkly Rep 2020;69:1265–1268. DOI: http://dx.doi.org/10.15585/mmwr.mm6936a6external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.